# ProQuest Investments

> ProQuest Investments is a VC fund backing Health Care and Biotechnology. See 37 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Princeton, United States
- Total investments: 37
- Last investment: Jan 2018
- Lead investor: 24%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/proquest-investments
- Website: http://www.proquestvc.com

ProQuest Investments is a VC fund in Princeton focused on Health Care and Biotechnology. Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management. We have 12 deal professionals and three offices, our headquarters in Princeton, and additional offices in San Diego and Montreal. We invest in healthcare companies seeking financings ranging from seed to late-stage. Our portfolioreflects the rich diversity of the healthcare industry and exemplifies our commitment to fostering the growth of exceptional businesses. In addition to our breadth of experience across many sectors of the healthcare industry, we have special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 40 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs. At the end of 2006, ProQuest Investments closed its fourth fund of $425 million.

## Contacts

5 contacts available for ProQuest Investments. Shizune tracks 4 team members at ProQuest Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/proquest-investments?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 18 | 49% |
| Biotechnology | 17 | 46% |
| Medical | 7 | 19% |
| Therapeutics | 7 | 19% |
| Pharmaceutical | 7 | 19% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 22% |
| Funding Round | 7 | 19% |
| Series A | 6 | 16% |
| Series C | 4 | 11% |
| Series D | 3 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 20 | 54% |
| Switzerland | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alain Schreiber | Partner | 15 | https://shizune.co/investors/profile/alain-schreiber |
| Jay Moorin | Partner | 5 | https://shizune.co/investors/profile/jay-moorin |
| Pasquale DeAngelis | CFO, Administrative Partner | 0 | https://shizune.co/investors/profile/pasquale-deangelis |
| Steven Ratoff | Venture Partner | 0 | https://shizune.co/investors/profile/steven-ratoff |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SomaLogic | SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $200M |  | Jan 03, 2018 |  |
| ReVision Optics | ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. | $32M |  | Nov 10, 2016 |  |
| Agile Therapeutics | Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol. The company was founded in 1997 as Levotech, Inc. and changed its name toAgile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey. | $20M | Post-IPO Equity | Feb 06, 2015 |  |
| SomaLogic | SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $16.5M |  | Nov 17, 2014 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $200M | Private Equity | Aug 04, 2014 |  |
| Telormedix | Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $6.8M | Series B | Dec 02, 2013 |  |
| Immune Design | Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-basedproducts for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence | $49M | Series C | Oct 30, 2013 |  |
| ReVision Optics | ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. | $55M | Series E | Jul 29, 2013 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $55M | Private Equity | Jun 25, 2013 |  |
| ReVision Optics | ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. | $15M | Series E | Apr 16, 2013 |  |

10 of 37 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 10 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 4 deals together
- [CHL Medical Partners](https://shizune.co/investors/profile/chl-medical-partners) — VC Fund, 4 deals together
- [InterWest Partners](https://shizune.co/investors/profile/interwest-partners) — VC Fund, 4 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does ProQuest Investments invest in?

ProQuest Investments invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Funding Round stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact ProQuest Investments?

Public channels for ProQuest Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at ProQuest Investments?

The team at ProQuest Investments includes Alain Schreiber (Partner), Jay Moorin (Partner) and Pasquale DeAngelis (CFO, Administrative Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co